188 related articles for article (PubMed ID: 27983933)
1. Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Li Y; Ji S; Fu LY; Jiang T; Wu D; Meng FD
Oncol Res; 2017 May; 25(5):721-731. PubMed ID: 27983933
[TBL] [Abstract][Full Text] [Related]
2. CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.
Zhang LP; Li WJ; Zhu YF; Huang SY; Fang SY; Shen L; Gao YL
Int J Clin Exp Pathol; 2015; 8(5):4535-44. PubMed ID: 26191143
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27.
Wang H; Chen H; Zhou H; Yu W; Lu Z
Oncol Res; 2017 Nov; 25(9):1431-1440. PubMed ID: 28109073
[TBL] [Abstract][Full Text] [Related]
4. Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Deng M; Wang J; Chen Y; Zhang L; Xie G; Liu Q; Zhang T; Yuan P; Liu D
Mol Med Rep; 2016 Aug; 14(2):1523-30. PubMed ID: 27314680
[TBL] [Abstract][Full Text] [Related]
5. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.
Dai W; Miao H; Fang S; Fang T; Chen N; Li M
Mol Med Rep; 2016 Aug; 14(2):1509-14. PubMed ID: 27314282
[TBL] [Abstract][Full Text] [Related]
6. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway.
Liu D; Zhang J; Wu Y; Shi G; Yuan H; Lu Z; Zhu Q; Wu P; Lu C; Guo F; Chen J; Jiang K; Miao Y
Int J Cancer; 2018 Apr; 142(7):1392-1404. PubMed ID: 29168185
[TBL] [Abstract][Full Text] [Related]
7. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
8. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies of cyclin-dependent kinase inhibitor 3 (CDKN3) in colorectal cancer.
Yang C; Sun JJ
Asian Pac J Cancer Prev; 2015; 16(3):965-70. PubMed ID: 25735390
[TBL] [Abstract][Full Text] [Related]
10. CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
Barrón EV; Roman-Bassaure E; Sánchez-Sandoval AL; Espinosa AM; Guardado-Estrada M; Medina I; Juárez E; Alfaro A; Bermúdez M; Zamora R; García-Ruiz C; Gomora JC; Kofman S; Pérez-Armendariz EM; Berumen J
PLoS One; 2015; 10(9):e0137397. PubMed ID: 26372210
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.
Yu C; Cao H; He X; Sun P; Feng Y; Chen L; Gong H
Biomed Pharmacother; 2017 Dec; 96():1109-1118. PubMed ID: 29196103
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of long noncoding RNA GHET1 inhibits cell‑cycle progression and invasion of gastric cancer cells.
Xia Y; Yan Z; Wan Y; Wei S; Bi Y; Zhao J; Liu J; Liao DJ; Huang H
Mol Med Rep; 2018 Sep; 18(3):3375-3381. PubMed ID: 30066922
[TBL] [Abstract][Full Text] [Related]
13. CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1.
Li WH; Zhang L; Wu YH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3614-3623. PubMed ID: 32329836
[TBL] [Abstract][Full Text] [Related]
14. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.
Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC
Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581
[TBL] [Abstract][Full Text] [Related]
15. CDKN3 expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma.
Chang SL; Chen TJ; Lee YE; Lee SW; Lin LC; He HL
Int J Med Sci; 2018; 15(10):992-998. PubMed ID: 30013440
[No Abstract] [Full Text] [Related]
16. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Xing C; Xie H; Zhou L; Zhou W; Zhang W; Ding S; Wei B; Yu X; Su R; Zheng S
Biochem Biophys Res Commun; 2012 Mar; 420(1):29-35. PubMed ID: 22390936
[TBL] [Abstract][Full Text] [Related]
17. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.
Cress WD; Yu P; Wu J
Int J Biochem Cell Biol; 2017 Oct; 91(Pt B):98-101. PubMed ID: 28504190
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Wang L; Sun L; Huang J; Jiang M
Cell Prolif; 2011 Jun; 44(3):291-9. PubMed ID: 21535270
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma.
Abdel-Tawab MS; Fouad H; Othman AM; Eid RA; Mohammed MA; Hassan A; Reyad HR
PLoS One; 2022; 17(4):e0265184. PubMed ID: 35446856
[TBL] [Abstract][Full Text] [Related]
20. GID2 Interacts With CDKN3 and Regulates Pancreatic Cancer Growth and Apoptosis.
Deng X; Ma J; Zhou W; Yuan Y; Wang B; Meng X
Lab Invest; 2023 Jun; 103(6):100122. PubMed ID: 36828188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
